Morgan Stanley Portfolio holdings
Morgan Stanley, founded in 1935 by Henry Sturgis Morgan and Harold Stanley as a spin-off from J.P. Morgan & Co., is a leading global financial services firm headquartered in New York City. Initially focused on investment banking, it has evolved into a diversified powerhouse offering wealth management, institutional securities, and asset management services, catering to corporations, governments, institutions, and high-net-worth individuals. With a strong presence in mergers and acquisitions, underwriting, and trading, Morgan Stanley manages billions in assets and is known for its sophisticated financial advisory services. The firm has adapted to modern markets by expanding its digital offerings and wealth management division, notably through its 2020 acquisition of E*TRADE, solidifying its position as a Wall Street titan.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.77B |
| 2 |
McKesson
MCK
|
+$2.38B |
| 3 |
SpaceX
SPCX
|
+$2.3B |
| 4 |
HONA
Honeywell Aerospace
HONA
|
+$2.05B |
| 5 |
Amazon
AMZN
|
+$1.37B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$5.96B |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$3.11B |
| 3 |
Honeywell
HON
|
+$1.96B |
| 4 |
Salesforce
CRM
|
+$1.47B |
| 5 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$775M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.02% |
| 2 | Technology | 24.63% |
| 3 | Financials | 9.78% |
| 4 | Healthcare | 7.32% |
| 5 | Industrials | 7.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1676
ACM Research
ACMR
$3.76B
| $88.8M | ﹤0.01% |
700,185
-492,520
| -41% | -$34.8M |
2018 Q1
33 quarters
|
|
1677
iShares MSCI Mexico ETF
EWW
$1.48B
| $88.8M | ﹤0.01% |
1,179,313
-236,653
| -17% | -$18.4M |
2013 Q2
52 quarters
|
|
1678
abrdn Physical Gold Shares ETF
SGOL
$6.96B
| $88.6M | ﹤0.01% |
2,317,629
+59,422
| +3% | +$2.55M |
2013 Q2
52 quarters
|
|
1679
Arrowhead Research
ARWR
$7.97B
| $88.4M | ﹤0.01% |
1,084,835
+124,328
| +13% | +$9.18M |
2013 Q3
51 quarters
|
|
1680
Calamos Strategic Total Return Fund
CSQ
$3.17B
| $88.4M | ﹤0.01% |
4,298,735
-67,478
| -2% | -$1.33M |
2013 Q2
52 quarters
|
|
1681
TG Therapeutics
TGTX
$8.32B
| $88M | ﹤0.01% |
1,601,714
+193,544
| +14% | +$7.92M |
2013 Q4
50 quarters
|
|
1682
Magnolia Oil & Gas
MGY
$6.79B
| $87.7M | ﹤0.01% |
3,429,471
+401,496
| +13% | +$11.5M |
2018 Q1
33 quarters
|
|
1683
Invesco Variable Rate Investment Grade ETF
VRIG
$1.87B
| $87.7M | ﹤0.01% |
3,498,471
+623,067
| +22% | +$15.6M |
2017 Q2
36 quarters
|
|
1684
Vicor
VICR
$9.01B
| $87.7M | ﹤0.01% |
230,808
-76,121
| -25% | -$20.8M |
2013 Q2
52 quarters
|
|
1685
Archrock
AROC
$5.18B
| $87.6M | ﹤0.01% |
2,152,724
-33,841
| -2% | -$1.25M |
2013 Q2
52 quarters
|
|
1686
Krystal Biotech
KRYS
$9.41B
| $87.5M | ﹤0.01% |
235,491
+26,409
| +13% | +$7.89M |
2018 Q2
32 quarters
|
|
1687
Full Truck Alliance
YMM
$9.07B
| $87.2M | ﹤0.01% |
10,736,456
+1,223,819
| +13% | +$10.4M |
2021 Q2
20 quarters
|
|
1688
Invesco S&P 500 Pure Growth ETF
RPG
$1.79B
| $87.2M | ﹤0.01% |
1,365,052
+33,993
| +3% | +$1.93M |
2013 Q2
52 quarters
|
|
1689
POSCO
PKX
$16.6B
| $87M | ﹤0.01% |
1,693,111
+544,471
| +47% | +$37.3M |
2013 Q2
52 quarters
|
|
1690
DELISTED
Catalyst Pharmaceutical
CPRX
| $86.8M | ﹤0.01% |
2,760,358
+73,059
| +3% | +$2.16M |
2014 Q3
47 quarters
|
|
1691
MDU Resources
MDU
$4.01B
| $86.7M | ﹤0.01% |
4,086,803
-134,722
| -3% | -$2.93M |
2013 Q2
52 quarters
|
|
1692
iShares iBonds Dec 2026 Term Corporate ETF
IBDR
$3.08B
| $86.6M | ﹤0.01% |
3,576,118
-174,100
| -5% | -$4.22M |
2017 Q1
37 quarters
|
|
1693
Enpro
NPO
$5.97B
| $86.6M | ﹤0.01% |
229,847
+26,875
| +13% | +$8.35M |
2013 Q2
52 quarters
|
|
1694
Globus Medical
GMED
$10.3B
| $86.5M | ﹤0.01% |
1,094,753
+34,253
| +3% | +$2.91M |
2013 Q2
52 quarters
|
|
1695
TCW Core Plus Bond ETF
FIXT
$224M
| $86.5M | ﹤0.01% |
2,288,612
+115,062
| +5% | +$4.34M |
2025 Q2
4 quarters
|
|
1696
Cal-Maine
CALM
$2.98B
| $86.4M | ﹤0.01% |
1,072,670
-42,418
| -4% | -$3.27M |
2013 Q2
52 quarters
|
|
1697
SLM Corp
SLM
$4.11B
| $86.4M | ﹤0.01% |
3,330,268
+560,033
| +20% | +$12.6M |
2013 Q2
52 quarters
|
|
1698
RLI Corp
RLI
$5.59B
| $86.4M | ﹤0.01% |
1,462,109
+145,789
| +11% | +$7.82M |
2013 Q2
52 quarters
|
|
1699
Global X MSCI Argentina ETF
ARGT
$706M
| $86.4M | ﹤0.01% |
945,964
+195,536
| +26% | +$18.2M |
2013 Q4
50 quarters
|
|
1700
Navios Maritime Partners
NMM
$2.55B
| $86.3M | ﹤0.01% |
1,232,168
+56,730
| +5% | +$4.06M |
2013 Q2
52 quarters
|
|
Similar funds
Morgan Stanley's Q2 2026 Portfolio in Review
As of Q2 2026, Morgan Stanley held 8,715 positions worth $1.89T, up 14% from $1.66T the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Morgan Stanley's Q2 2026 filing shows 425 new, 3,807 increased, 3,215 reduced and 303 closed positions. Its largest new stake was SpaceX: 13,532,773 shares worth $2.31B. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $5.96B.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, down from 27% a quarter earlier, followed by Technology and Financials.
- Morgan Stanley's largest Q2 2026 buy was SpaceX: 13,532,773 shares worth $2.31B.
- Morgan Stanley added most to NVIDIA in Q2 2026, an estimated $2.77B increase.
- Morgan Stanley's biggest Q2 2026 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $5.96B.
- Morgan Stanley fully exited Apellis Pharmaceuticals in Q2 2026, selling an estimated $404M.
- Morgan Stanley's ten largest holdings make up 21% of its $1.89T portfolio in Q2 2026.
- Morgan Stanley opened 425 new positions and closed 303 in Q2 2026.
- Morgan Stanley's portfolio value rose 14% quarter-over-quarter to $1.89T.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.